Universal reference book for medicines
Product name: NEUROX ® (NEUROX)

Active substance: nonappropriate

Type: Antioxidant drug

Manufacturer: ФармФірма СОТЕКС (Russia)
Composition, form of production and packaging
The solution for intravenous and /
or injection is colorless or slightly yellowish, transparent.

1 ml of 1 amp.

ethylmethylhydroxypyridine succinate 50 mg 250 mg

Excipients: sodium disulfite - 1 mg, water d / u - up to 1 ml.

5 ml - dark glass ampoules (5) - packings, cell planimetric (1) - packs of cardboard.

5 ml - ampoules of dark glass (5) - packings of cellular contour (2) - packs cardboard.

5 ml - ampoules of dark glass (5) - packings of cellular contour (4) - packs cardboard.

The solution for intravenous and / or injection is colorless or slightly yellowish, transparent.

1 ml of 1 amp.

ethylmethyl hydroxypyridine succinate 50 mg 100 mg

Excipients: sodium disulfite - 1 mg, water d / u - up to 1 ml.

2 ml - dark glass ampoules (5) - packings of cellular contour (1) - packs of cardboard.

2 ml - ampoules of dark glass (5) - packings of cellular contour (2) - packs cardboard.

2 ml - ampoules of dark glass (5) - packings of cellular contour (4) - packs cardboard.

2 ml - dark glass ampoules (5) - packings, cellular outline (10) - packs of cardboard.

The solution for intravenous and / or injection is colorless or slightly yellowish, transparent.

1 ml of 1 amp.

ethylmethyl hydroxypyridine succinate 50 mg 500 mg

Excipients: sodium disulfite - 1 mg, water d / u - up to 1 ml.

10 ml - dark glass ampoules (1) - packings of cellular contour (1) - packs cardboard.

The solution for intravenous and / or injection is colorless or slightly yellowish, transparent.

1 ml of 1 amp.

ethylmethyl hydroxypyridine succinate 50 mg 1000 mg

Excipients: sodium disulfite - 1 mg, water d / u - up to 1 ml.

20 ml - dark glass ampoules (1) - packings of cellular contour (1) - packs of cardboard.

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2013.

PHARMACHOLOGIC EFFECT

Antioxidant drug.
Ethylmethylhydroxypyridine succinate (EMGPS) is an inhibitor of free radical processes, a membrane protector possessing antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects. It belongs to the class of 3-hydroxypyridines. The mechanism of action is due to antioxidant and membrane-protective properties. Suppresses lipid peroxidation, increases the activity of superoxide oxidase, increases the ratio of lipid-protein, improves the structure and function of the cell membrane. Modulates the activity of membrane-bound enzymes, receptor complexes, which facilitates their binding to ligands, preservation of the structural and functional organization of biomembranes, transport of neurotransmitters and improvement of synaptic transmission. Increases the concentration of dopamine in the brain. Enhances compensatory activation of aerobic glycolysis and reduces the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia with an increase in adenosine triphosphate and creatine phosphate, activates the energy-producing function of mitochondria.
Increases the resistance of the body to the effects of various damaging factors in pathological conditions (shock, hypoxia and ischemia, cerebral circulation disorders, intoxication with ethanol and antipsychotic drugs).
It improves the metabolism and blood supply of the brain, microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membranes of blood cells (erythrocytes and platelets), reducing the likelihood of hemolysis. Has hypolipidemic action, reduces the content of total cholesterol and LDL. Normalizes metabolic processes in the ischemic myocardium, reduces the necrosis zone, restores and / or improves electrical activity and contractility of the myocardium, and also increases coronary blood flow in the ischemia zone, increases the antianginal activity of nitro drugs, reduces the effects of reperfusion syndrome in acute coronary insufficiency.
The stress-protective action is manifested in the normalization of post-stress behavior, somatovegetative disorders, the restoration of sleep-wake cycles, disrupted learning and memory processes, and the reduction of dystrophic changes in various structures of the brain.

EMGPS has a pronounced antitoxic effect in the withdrawal syndrome, eliminates neurologic and neurotoxic manifestations of acute alcohol intoxication, corrects behavioral and cognitive impairment.
Under the influence of ethylmethylhydroxypyridine succinate, the effect of tranquilizing, neuroleptic, antidepressant, hypnotics and anticonvulsants is enhanced, which allows to reduce their doses and reduce side effects.
PHARMACOKINETICS

Suction

With the / m administration of the drug is determined in the blood plasma for 4 hours after administration.
With the / m introduction of T max in plasma is 0.3-0.58 hours. With the / m introduction in a dose of 400-500 mg C max in plasma - 2.5-4 μg / ml.
Distribution

EMGPS quickly passes from the bloodstream into the organs and tissues and is rapidly excreted from the body.
The average retention time of the drug in the body with the / m introduction is 0.7-1.3 hours.
Metabolism and excretion

Metabolized in the liver by glucuronation.

It is quickly excreted in the urine mainly in the form of metabolites (50% in 12 hours) and in a small amount - unchanged (0.3% per 12 hours).
The most intense withdrawal within the first 4 hours after taking the drug. The indices of excretion in the urine of unchanged drug and metabolites have a significant individual variability.
INDICATIONS

- acute disorders of cerebral circulation (as part of complex therapy);

- encephalopathy;

- cardiopsychoneurosis;

- mild cognitive impairment of atherosclerotic origin;

- anxiety states in neurotic and neurosis-like states;

- An abstinence syndrome with alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;

- acute intoxication with antipsychotic drugs.

DOSING MODE

The drug is given in / m or in / in (jet or drip).
With the infusion method of administration, the drug should be diluted in 0.9% sodium chloride solution.
Doses are selected individually.
The initial dose is 50-100 mg 1-3 times / day, which is gradually increased to obtain a therapeutic effect.
In / in the jet Neuroks injected slowly for 5-7 minutes, drip - at a speed of 40-60 drops / min.

The maximum daily dose is 800 mg.

In acute disorders of cerebral circulation Neuroks are used as part of complex therapy in the first 2-4 days IV drip 200-300 mg 1 time / day, then in / m at 100 mg 3 times / day.
The duration of treatment is 10-14 days.
With discirculatory encephalopathy in the phase of decompensation - in / in jet or drip in a dose of 100 mg 2-3 times / day for 14 days, then - in / m at 100 mg / day for the next 14 days.

For the course of prophylaxis of discirculatory encephalopathy - in / m in a dose of 100 mg 2 times / day for 10-14 days.

With neurocirculatory dystonia, neurotic and neurosis-like conditions - in / m at 50-400 mg / day for 14 days.

With abstinent alcohol syndrome - in / m in a dose of 100-200 mg 2-3 times / day or intravenously drip 1-2 times / day for 5-7 days.

In acute intoxication with antipsychotic drugs - IV in a dose of 50-300 mg / day for 7-14 days.

With mild cognitive impairment in elderly patients and with anxiety disorders - in / m in a dose of 100-300 mg / day for 14-30 days.

SIDE EFFECT

When parenterally administered (especially in / in the jet): dryness and metallic taste in the mouth, sensation of "spilling heat" throughout the body, sore throat and chest discomfort, a feeling of lack of air (usually associated with an excessively high rate of administration and are short-term).

With prolonged use: nausea, flatulence, sleep disturbances (drowsiness or falling asleep).

Possible: allergic reactions.

CONTRAINDICATIONS

acute renal failure;

acute liver failure;

- Pregnancy;

- lactation period (breastfeeding);

- childhood;

- Hypersensitivity to the components of the drug.

With caution should prescribe the drug for allergic diseases and reactions in the anamnesis.

PREGNANCY AND LACTATION

The drug is contraindicated in pregnancy and during breastfeeding.

APPLICATION FOR FUNCTIONS OF THE LIVER

Contraindicated in acute renal failure.

APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS

Contraindicated in acute liver failure.

APPLICATION FOR CHILDREN

Contraindicated in childhood.

APPLICATION IN ELDERLY PATIENTS

The application is possible according to the dosing regimen.

SPECIAL INSTRUCTIONS

Impact on the ability to drive vehicles and manage mechanisms

During the treatment period, patients should be careful when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

OVERDOSE

Symptoms: sleep disorders (insomnia, in some cases - drowsiness);
with iv introduction - a slight and short-term (up to 1.5-2 h) increase in blood pressure.
Treatment: as a rule, the symptoms disappear on their own within a day.
In severe cases with insomnia, nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg; with excessive increase in blood pressure - antihypertensive drugs under the control of blood pressure.
DRUG INTERACTION

Strengthens the action of benzodiazepine anxiolytics, antiepileptic (carbamazepine), antiparkinsonian (levodopa) drugs, nitrates.

Reduces the toxic effects of ethanol.

TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

List B. The drug should be stored out of reach of children, dry, protected from light at a temperature of no higher than 25 ° C.
Shelf life - 3 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!